3β,17β-dihydroxyandrost-5-en-7-one | 2226-65-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3β,17β-dihydroxyandrost-5-en-7-one
• 英文别名: 3beta,17beta-Dihydroxyandrost-5-en-7-one；(3S,8R,9S,10R,13S,14S,17S)-3,17-dihydroxy-10,13-dimethyl-1,2,3,4,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-7-one
• CAS: 2226-65-5
• 化学式: C₁₉H₂₈O₃
• 分子量: 304.43
• InChiKey: DFFWENNZWHOWSC-LXKHFVGGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3β,17β-dihydroxyandrost-5-en-7-one 在 potassium tri-sec-butyl-borohydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以58%的产率得到androst-5-ene-3β,7α,17β-triol
  参考文献：
  名称：

  C19-Steroids as androgen receptor modulators: Design, discovery, and structure-activity relationship of new steroidal androgen receptor antagonists

  摘要：

  Dehydroepiandrosterone (DHEA), the most abundant steroid in human circulating blood, is metabolized to sex hormones and other C-19-steroids. Our previous collaborative study demonstrated that androst-5-ene-3 beta,17 beta-diol (Adiol) and androst-4-ene-3,17-dione (Adione), metabolites of DHEA, can activate androgen receptor (AR) target genes. Adiol is maintained at a high concentration in prostate cancer tissue; even after androgen deprivation therapy and its androgen activity is not inhibited by the antiandrogens currently used to treat prostate cancer patients. We have synthesized possible metabolites of DHEA and several synthetic analogues and evaluated their role in androgen receptor transactivation to identify AR modulators. Steroids with low androgenic potential in PC-3 cell lines were evaluated for anti-dihydrotestosterone (DHT) and anti-Adiol activity. We discovered three potent antiandrogens: 3 beta-acetoxyandrosta-1,5-diene-17-one 17-ethylene ketal (ADEK), androsta-1,4-diene-3,17-dione 17-ethylene ketal (OAK), and 3 beta-hydroxyandrosta-5,16-diene (HAD) that antagonized the effects of DHT as well as of Adiol on the growth of LNCaP cells and on the expression of prostate-specific antigen (PSA). In vivo tests of these compounds will reveal their potential as potent antiandrogens for the treatment of prostate cancer. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.05.022
• 作为产物：
  描述：

  7-羟基去氢表雄酮 在 Mortierella isabellina AM₂₁₂ fungal strain 作用下， 反应 24.0h， 生成 3β,17β-dihydroxyandrost-5-en-7-one
  参考文献：
  名称：

  DHEA的羟化，雄烯二醇和雄酮黄被孢霉AM212。证据表明，组成型和诱导型羟化酶均催化5-烯底物的7α-和7β-羟基化

  摘要：

  DHEA的转型过程， 雄烯二醇 和 表雄甾酮在黄被孢霉AM212文化的影响。所提到的底物进行了有效的羟基化。5烯底物– DHEA和雄烯二醇 –被转化为7α-和7β-烯丙醇的混合物，而 表雄甾酮 被转化为7α-（主要是），11α-和9α-单羟基衍生物。 酮康唑和环己酰亚胺的抑制研究表明，伊萨贝拉霉中存在组成型和底物诱导的羟化酶。在时间过程的基础上分析脱氢表雄酮和雄烯二醇，烯丙基C中的氧化7 -H α和C 7 -H β键由相同的酶是一个合理的假设。

  DOI：

  10.1039/c1ob05350g

文献信息

• Hydroxylation of DHEA and its analogues by Absidia coerulea AM93. Can an inducible microbial hydroxylase catalyze 7α- and 7β-hydroxylation of 5-ene and 5α-dihydro C19-steroids?
  作者：Natalia Milecka-Tronina、Teresa Kołek、Alina Świzdor、Anna Panek

  DOI：10.1016/j.bmc.2013.11.050

  日期：2014.1

  coerulea AM93. DHEA and androstenediol were transformed to the mixture of allyl 7-hydroxy derivatives, while EpiA and 5α-androstan-3,17-dione were converted mainly to 7α- and 7β-alcohols accompanied by 9α- and 11α-hydroxy derivatives. On the basis of (i) time course analysis of hydroxylation of the abovementioned substrates, (ii) biotransformation with resting cells at different pH, (iii) enzyme inhibition

  在本文中，我们着重研究了Absidia coerulea AM93对DHEA，雄烯二醇，表雄甾酮和5α-雄烷-3,17-二酮进行7-羟基化的过程。除此之外，我们提出了对蓝藻中类固醇的羟基化的初步分析。AM93。DHEA和雄烯二醇被转化为烯丙基7-羟基衍生物的混合物，而EpiA和5α-雄烷-3,17-二酮主要转化为7α-和7β-醇，并伴有9α-和11α-羟基衍生物。基于（i）上述底物羟基化的时程分析，（ii）在不同pH下静息细胞的生物转化，（iii）酶抑制分析以及（iv）底物C–H键之间的几何关系经历羟基化和辅因子结合的活性氧原子，但假定相同的酶可催化氧化ç 7 -H α以及为C 7 -H β在-5-烯和5α二氢C键19-类固醇。在底物的结构和羟基化的区域选择性之间观察到的相关性表明，正常的结合酶-底物复合物中可能发生7β-羟基化，而在反向反向结合复合物中则发生7α-羟基化。
• Novel Stereoselective Synthesis of 7β-Methyl-Substituted 5-Androstene Derivatives
  作者：Yunhong Zheng、Yuanchao Li

  DOI：10.1021/jo020290x

  日期：2003.2.1

  The 7beta-methyl-5-androstene derivatives 11a-c were prepared in good yield with high stereoselectivities starting from 3beta-acetoxyandrost-5-en-17-one 4. The addition of methylmagnesium iodide to the 7-carbonyl group of 7a-c gave, after hydrolysis, two isomers 9a-c and 10a-c, which were stereoselectively deoxygenated by means of an ionic hydrogenation to afford the compounds 11a-c.

  从3β-乙酰氧基-雄烷-5-en-17-one 4开始，以高收率和高立体选择性制备7β-甲基-5-雄烯衍生物11a-c。将甲基碘化镁加到7a-c的7-羰基上在水解后，得到两个异构体9a-c和10a-c，它们通过离子氢化被立体选择性地脱氧，得到化合物11a-c。
• Blood cell deficiency treatment method
  申请人：——

  公开号：US20030083231A1

  公开（公告）日：2003-05-01

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3&bgr;-yl)-&bgr;-D-glucopyranosiduronate, 16&agr;,3&agr;-dihydroxy-5&agr;-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  该发明涉及使用化合物治疗多种疾病，如血小板减少症、中性粒细胞减少症或放疗延迟效应。可以用于该发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-3β-基)-β-D-葡糖吡喃糖醛酸酯、16α,3α-二羟基-5α-雄甾酮-17-酮或3,7,16,17-四羟基雄烷-5-烯、3,7,16,17-四羟基雄烷-4-烯、3,7,16,17-四羟基雄烷-1-烯或3,7,16,17-四羟基雄烷可用于治疗方法中。
• Ergosteroids VII: perchloric acid-induced transformations of 7-oxygenated steroids and their bio-analytical applications—a liquid chromatographic-mass spectrometric study
  作者：Ashok Marwah、Padma Marwah、Henry Lardy

  DOI：10.1016/s0045-2068(02)00010-x

  日期：2002.8

  Sulfate esters of 7-oxo-delta(5)-steroids can be selectively and quantitatively hydrolyzed to the corresponding free steroids in the presence of carboxylic acid esters by solvolysis with perchloric acid in ethyl acetate at room temperature. Sulfates as well as carboxylic acid esters, methyl ethers, and ketals can be quantitatively converted to the corresponding 3,5-diene-7-one derivatives by heating

  通过在室温下用高氯酸在乙酸乙酯中进行溶剂分解，可以在羧酸酯存在下将7-氧代-δ（5）-甾族化合物的硫酸酯选择性地和定量地水解为相应的游离甾体。通过在65°C的甲醇中与高氯酸加热，可以将硫酸盐以及羧酸酯，甲基醚和缩酮定量转化为相应的3,5-二烯-7-一衍生物。二烯具有较强的紫外线吸收能力最大中心在284 nm附近。这些反应已用于表征和解析结构复杂的生物基质中存在的7-氧化的delta（5）-类固醇，也可用于定量估计总的7-oxo-delta（5）-类固醇（在生物基质中是游离的还是结合的）。
• Compositions and treatment methods
  申请人：Ahlem N. Clarence

  公开号：US20060079492A1

  公开（公告）日：2006-04-13

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  本发明涉及使用化合物治疗多种疾病，例如血小板减少症、中性粒细胞减少症或放射治疗的延迟影响。可用于本发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-5-烯-3β-基)-β-D-葡萄糖吡喃糖醇酸酯、16α,3α-二羟基-5α-雄甾烷-17-酮或3,7,16,17-四羟基雄烯-5-烯、3,7,16,17-四羟基雄烯-4-烯、3,7,16,17-四羟基雄烯-1-烯或3,7,16,17-四羟基雄甾烷可用于治疗方法。